To include your compound in the COVID-19 Resource Center, submit it here.

TNKase tenecteplase: Marketed in U.S.; under review in Europe

Patients given TNKase plus Clexane had an event rate of 13.75% compared to 17.04% for TNKase and UFH (p=0.0081). The TNKase plus UFH and ReoPro

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE